ARC Therapies
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
National Cancer Center Japan spin-out developing novel cell and gene therapies for oncology, with programs targeting ATLL and microbiome-based immunotherapies.
Oncology
Technology Platform
Cell therapy platform leveraging National Cancer Center Japan's tumor immunology research, with programs in T-cell therapies and microbiome-based cancer immunotherapies.
Opportunities
Leveraging Japan's National Cancer Center research for first-in-class cell therapies, addressing Japan-endemic cancers like ATLL, and combining cell therapy with microbiome modulation for novel immunotherapies.
Risk Factors
Early-stage preclinical programs with unproven clinical efficacy, dependency on academic collaborations, and competition from established global cell therapy companies with more advanced platforms.
Competitive Landscape
Competes with global cell therapy leaders (Novartis, Gilead, BMS) and Japanese oncology biotechs; differentiates through National Cancer Center Japan research access and focus on Japan-specific oncology needs like ATLL.